Cargando…

A Meta-Analysis Evaluating the Effectiveness and Safety of Upadacitinib in Treating Rheumatoid Arthritis in Patients With Inadequate Response to Disease-Modifying Anti-Rheumatic Drugs

Upadacitinib, an oral Janus kinase (JAK) inhibitor, is used to manage rheumatoid arthritis. The objective was to generate statistical evidence from the existing data for upadacitinib efficacy and safety in various treatment regimens with different dosages in active rheumatoid arthritis patients. We...

Descripción completa

Detalles Bibliográficos
Autores principales:	Panchal, Viraj, Vyas, Bhavya H, Sivasubramanian, Barath Prashanth, Panchal, Kanan, Patel, Harshank
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2023
Materias:	Internal Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9976645/ https://www.ncbi.nlm.nih.gov/pubmed/36874682 http://dx.doi.org/10.7759/cureus.34384

Ejemplares similares

Crystalloid Solutions in Hospital: A Review of Existing Literature
por: Panchal, Viraj, et al.
Publicado: (2023)

Upadacitinib for rheumatoid arthritis
Publicado: (2020)

The Safety Profile of Upadacitinib in Patients with Rheumatoid Arthritis in Japan
por: Yamaoka, Kunihiro, et al.
Publicado: (2021)

Upadacitinib in patients from China, Brazil, and South Korea with rheumatoid arthritis and an inadequate response to conventional therapy
por: Zeng, Xiaofeng, et al.
Publicado: (2021)

Motivations for inadequate persistence with disease modifying anti-rheumatic drugs in early rheumatoid arthritis: the patient’s perspective
por: Pascual-Ramos, Virginia, et al.
Publicado: (2013)

Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXT
por: Strand, Vibeke, et al.
Publicado: (2019)

An Unusual Presentation of Juvenile Polymyositis in an Adolescent Girl
por: Patel, Rushi, et al.
Publicado: (2023)

Lymphomatoid papulosis during upadacitinib treatment for rheumatoid arthritis
por: Iinuma, Shin, et al.
Publicado: (2022)

Upadacitinib for Patients with Rheumatoid Arthritis: A Comprehensive Review
por: Sanmartí, Raimon, et al.
Publicado: (2023)

Correction to: Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXT
por: Strand, Vibeke, et al.
Publicado: (2020)

Tocilizumab efficacy and safety in rheumatoid arthritis patients after inadequate response to disease-modifying anti-rheumatic drugs or anti-tumor necrosis factor
por: Abdulkader, Omer Ahmad Fatheddin, et al.
Publicado: (2016)

Janus Kinase Inhibitors in Rheumatoid Arthritis: An Update on the Efficacy and Safety of Tofacitinib, Baricitinib and Upadacitinib
por: Harrington, Robert, et al.
Publicado: (2023)

Patient-reported outcomes of upadacitinib versus abatacept in patients with rheumatoid arthritis and an inadequate response to biologic disease-modifying antirheumatic drugs: 12- and 24-week results of a phase 3 trial
por: Bergman, Martin, et al.
Publicado: (2022)

The role of upadacitinib in the treatment of moderate-to-severe active rheumatoid arthritis
por: Avci, Ali Berkant, et al.
Publicado: (2021)

Kaposi sarcoma in a patient treated with upadacitinib for rheumatoid arthritis
por: Fournier, Cynthia, et al.
Publicado: (2023)

Correction: Patient-reported outcomes of upadacitinib versus abatacept in patients with rheumatoid arthritis and an inadequate response to biologic disease-modifying antirheumatic drugs: 12- and 24-week results of a phase 3 trial
por: Bergman, Martin, et al.
Publicado: (2022)

Efficacy and safety of upadacitinib over 84 weeks in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE)
por: Kameda, Hideto, et al.
Publicado: (2021)

Clinical Pharmacokinetics of Upadacitinib: Review of Data Relevant to the Rheumatoid Arthritis Indication
por: Mohamed, Mohamed-Eslam F., et al.
Publicado: (2019)

Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs
por: Strand, Vibeke, et al.
Publicado: (2019)

Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme
por: Cohen, Stanley B, et al.
Publicado: (2021)

Safety of upadacitinib in Latin American patients with rheumatoid arthritis: an integrated safety analysis of the SELECT phase 3 clinical program
por: Kakehasi, Adriana Maria, et al.
Publicado: (2023)

Upadacitinib for the treatment of psoriatic arthritis
por: Fonseca, Diogo, et al.
Publicado: (2023)

Benefit–Risk Analysis of Upadacitinib Compared with Adalimumab in the Treatment of Patients with Moderate-to-Severe Rheumatoid Arthritis
por: Conaghan, Philip, et al.
Publicado: (2021)

Rapunzel Syndrome in a Teenage Girl: A Case Report
por: Sivasubramanian, Barath Prashanth, et al.
Publicado: (2022)

Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis
por: Biggioggero, Martina, et al.
Publicado: (2019)

Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis
por: Burmester, Gerd R, et al.
Publicado: (2023)

Efficacy and safety of baricitinib for active rheumatoid arthritis in patients with an inadequate response to conventional synthetic or biological disease-modifying anti-rheumatic drugs: A meta-analysis of randomized controlled trials
por: Wu, Zhi-Peng, et al.
Publicado: (2018)

MACE and VTE across upadacitinib clinical trial programmes in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis
por: Charles-Schoeman, Christina, et al.
Publicado: (2023)

Switching between Janus kinase inhibitor upadacitinib and adalimumab following insufficient response: efficacy and safety in patients with rheumatoid arthritis
por: Fleischmann, Roy M, et al.
Publicado: (2021)

Rheumatoid Neuropathy: A Brief Overview
por: Rajeshwari, Bhavya, et al.
Publicado: (2023)

Comprehensive Review of Red Meat Consumption and the Risk of Cancer
por: Sivasubramanian, Barath Prashanth, et al.
Publicado: (2023)

Gout, Rheumatism, and Rheumatoid Arthritis
Publicado: (1900)

Chronic Rheumatism and Rheumatoid Arthritis
por: Lindsay, J.
Publicado: (1908)

Efficacy and safety of upadacitinib in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE): a placebo-controlled phase IIb/III study
por: Kameda, Hideto, et al.
Publicado: (2020)

Exposure–Response Analyses of Upadacitinib Efficacy and Safety in Phase II and III Studies to Support Benefit–Risk Assessment in Rheumatoid Arthritis
por: Nader, Ahmed, et al.
Publicado: (2019)

Upadacitinib in Rheumatoid Arthritis: A Benefit–Risk Assessment Across a Phase III Program
por: Conaghan, Philip G., et al.
Publicado: (2021)

Efficacy and safety of low-dose tacrolimus for active rheumatoid arthritis with an inadequate response to methotrexate
por: Lee, Won-Seok, et al.
Publicado: (2016)

Upadacitinib as monotherapy and in combination with non-biologic disease-modifying antirheumatic drugs for psoriatic arthritis
por: Nash, Peter, et al.
Publicado: (2021)

The Role of Biologics in Rheumatoid Arthritis: A Narrative Review
por: Patel, Jay P, et al.
Publicado: (2023)

An Analysis of Rheumatoid Arthritis Hospitalizations
por: Kannayiram, Sandhya Shri, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_mtk6cc8mokp8m97na62f9clst2